

Novavax Investor Relations

GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard's efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.

Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.

"Dr. Stoddard is a foundational building block of the Novavax commercial team," said John Trizzino, Senior Vice President, Commercial Operations. "His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate."

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.

Contact:

Novavax, Inc. Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir@novavax.com
240-268-2000

Russo Partners, LLC David Schull Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

<https://ir.novavax.com/2016-01-08-Novavax-Appoints-Jeffrey-Stoddard-M-D-Vice-President-Medical-Affairs>